AMAG Reports Fourth Quarter And Full Year 2016 Financial Results

WALTHAM, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today reported unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2016.

Total GAAP revenue for the full year of 2016 increased approximately 27% to $532.1 million, primarily driven by record sales for both Makena® (hydroxyprogesterone caproate injection) and Feraheme® (ferumoxytol) and the recognition of a full year of service revenues from Cord Blood Registry® (CBR), which AMAG acquired in August 2015. The company reported operating income of $78.9 million in 2016. Non-GAAP adjusted EBITDA increased approximately 24% to $265.7 million in 2016.1

Back to news